Carregant...

Application of CRISPR/Cas9 Technology to HBV

More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Guigao Lin, Kuo Zhang, Jinming Li
Format: Artigo
Idioma:Inglês
Publicat: MDPI AG 2015-11-01
Col·lecció:International Journal of Molecular Sciences
Matèries:
HBV
Accés en línia:http://www.mdpi.com/1422-0067/16/11/25950
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!